Radient Pharmaceuticals To Present Onko-SureTM Cancer Test At Prestigious ASCO Annual Oncology Conference

Main Category: Cancer / Oncology
Also Included In: Conferences;  Blood / Hematology
Article Date: 04 Jun 2010 - 5:00 PDT

email to a friend   printer friendly   opinions  

Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced it is attending and presenting at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago June 4-8, 2010.

ASCO is the world's leading professional organization representing physicians who care for people with cancer. With more than 27,000 oncology practitioners as members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. More than 30,000 cancer specialists from around the world are expected to gather at the meeting to discuss the latest innovations in cancer research, product and testing quality, practice and technology.

According to Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals, "RPC is excited to be an active participant at ASCO, an event that represents the largest gathering of physicians, scientists and oncology experts. This year's event serves as an ideal venue for RPC to share its latest scientific and product developments, company progress and market developments."

In addition to Douglas MacLellan, RPC's Director of Oncology, Dr. Motamed-Khorasani and Christopher Gee, Director of International Sales and Marketing will be on hand at Booth 13148, to speak with event attendees about RPC's proprietary Onko-Sure™ in vitro diagnostic (IVD) cancer test and the Company's worldwide commercialization strategy.

Those interested in pre-scheduling a meeting with RPC at ASCO may contact cgee@radient-pharma.com or call 310-562-6783. Additional information regarding RPC's Onko-Sure IVD cancer test is available here. Radient Pharmaceuticals' subsidiary AMDL Diagnostics Inc. will provide additional updates regarding their participation at ASCO via its corporate website at http://www.radient-pharma.com.

Onko-Sure™ is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection, screening, and monitoring of various types of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure™ is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer detection and monitoring test.

Source
Radient Pharmaceuticals
ASCO

• Additional
• References
• Citations